What the data say about asymptomatic COVID infections

From Nature News, 18 November 2020: How many people don’t experience any symptoms after becoming infected with SARS-CoV-2? And what is their role in spreading COVID-19? These have been key questions since the beginning of the pandemic. Now, evidence suggests that about one in five infected people will experience no symptoms, and they will transmit Continue reading What the data say about asymptomatic COVID infections

A terrible, terrible failure’: Richard Horton on the COVID-19 response

From The Medical Republic, 28 September 2020: Richard Horton is angry. Early in the COVID-19 pandemic in the United Kingdom, the editor-in-chief of international medical journal The Lancet began receiving messages from frontline healthcare workers. Increasingly terrified and desperate staff with inadequate or no PPE were being sent in to deal with what was clearly a deadly Continue reading A terrible, terrible failure’: Richard Horton on the COVID-19 response

Longevity, quality and turning back the clock

From Griffith Review, April 2020: My Nan was an active, outgoing, engaged senior citizen. She gardened, kneeling on a foam pad to protect the skin of her knees and her fragile bones, honeycombed with osteoporosis. She read books, the newspaper, did the crosswords. She looked after her neighbours’ children for an afternoon here and there, Continue reading Longevity, quality and turning back the clock

How Indian scientists have been scrambling to contain antimicrobial resistance for years

From Nature Careers India, 1 April 2020: In 2017, the World Health Organization (WHO) came up with a new classification system for antibiotics on its essential medicines list: Access, Watch, and Reserve. Antibiotics on the Access list were narrow spectrum antibiotics — only effective against a small range of organisms — that would be recommended Continue reading How Indian scientists have been scrambling to contain antimicrobial resistance for years

The challenge of delivering RNA-interference therapeutics to their target cells

From Nature, 16 October 2019: The commercial story of RNA interference (RNAi) harbours more plot twists and unexpected demises than television fantasy drama Game of Thrones. As in all good dramas, there was someone — or something — that, just as things were looking promising, showed up to foil everyone’s plans, in this case hindering Continue reading The challenge of delivering RNA-interference therapeutics to their target cells

Nature killer cell therapies catch up to CAR-T

From The Scientist, 1 April 2020: When the first anticancer therapies based on engineered T cells hit the market a few years ago, they offered the possibility of what would have once been perceived as a medical miracle: a one-shot cure for certain blood cancers. Chimeric antigen receptor (CAR) T cell therapies, as they are Continue reading Nature killer cell therapies catch up to CAR-T

Immunity and our DNA: why women are the stronger sex

From the Sydney Morning Herald, 24 April 2020: For thousands of years, women have been denigrated as the weaker sex, men’s inferior in cognitive and physical abilities, in need of their protection and support, vulnerable and flawed. Oh, how the tables have turned, and not a moment too soon. With a virulent and deadly pathogen Continue reading Immunity and our DNA: why women are the stronger sex

Game-changing class of immunotherapy drugs lengthens melanoma survival rates

From Nature, 22 April 2020: When Jedd Wolchok began working in the area of melanoma 20 years ago, the average life expectancy for a patient with advanced disease was six or seven months. Now his waiting room is full of people coming back for their third or fourth year of follow-up, sharing their stories of Continue reading Game-changing class of immunotherapy drugs lengthens melanoma survival rates